Evidence map›Paper›PMID 42243279›Full record

ArticleScientific reports2026

Generation of anti-bovine CD20 monoclonal antibody with cytotoxic activity for the depletion of bovine B-cell lymphoma cells.

Shuya Mitoma, Tomofumi Uto, Tomohiro Fukaya, Nao Yamanokuchi, Yumiko Sato, Yotaro Nishikawa, Shoichi Wakitani, Naoyuki Fuke, Go Kitahara, Satoshi Sekiguchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuya MitomaDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Tomofumi UtoDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Tomohiro FukayaDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Nao YamanokuchiDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Yumiko SatoDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Yotaro NishikawaDepartment of Dermatology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan.
Shoichi WakitaniDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, 1-1, Gakuen Kibanadai-Nishi, Miyazaki, 889-2192, Japan.
Naoyuki FukeDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, 1-1, Gakuen Kibanadai-Nishi, Miyazaki, 889-2192, Japan.
Go KitaharaDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, 1-1, Gakuen Kibanadai-Nishi, Miyazaki, 889-2192, Japan.
Satoshi SekiguchiDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, 1-1, Gakuen Kibanadai-Nishi, Miyazaki, 889-2192, Japan.
Masahiro YasudaDepartment of Veterinary Medicine, Faculty of Agriculture, University of Miyazaki, 1-1, Gakuen Kibanadai-Nishi, Miyazaki, 889-2192, Japan.
Katsuaki SatoDivision of Immunology, Department of Infectious Disease, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki, 889-1692, Japan. katsuaki_sato@med.miyazaki-u.ac.jp.

Funding

Scientific Research (B) from the Ministry of Education, Science and Culture of Japan 23H02773Scientific Research (B) from the Ministry of Education, Science and Culture of Japan 25K02533Scientific Research (C) from the Ministry of Education, Science and Culture of Japan 23K06768
6 · The paper itself

Abstract

Bovine leukemia virus (BLV) is the causative agent of enzootic bovine leukosis (EBL), which manifests as B-cell lymphomas in cattle. However, the effective therapy for EBL has not yet been developed. While the usage of anti-human CD20 monoclonal antibody (mAb) for B-cell depletion therapy (BCDT) can provide remarkable curative effects on several types of B-cell tumors in humans, this approach remains problematic in cattle due to the lack of anti-bovine CD20 (boCD20) mAb for BCDT. Here, we show that newly developed mAb targeting boCD20 utilizes effector function to deplete EBL-driven B-cell lymphoma cells and bovine B cells. Anti-boCD20 mAb not only specifically recognized boCD20 but also exhibited the cytotoxic function against EBL-derived B-cell lymphoma cells and bovine B cells mediated through Ab-dependent cell-mediated cytotoxicity (ADCC) and complement-mediated cytotoxicity (CDC) as well as direct cell death. Furthermore, the treatment of immunodeficient mice transplanted with EBL-derived B-cell lymphoma cells with anti-boCD20 mAb led to inhibition of their growth. Thus, our findings highlight boCD20 as a valid marker for identifying B cells and EBL-derived B-cell lymphoma cells in cattle and provide support for boCD20 as a potential target for mAb-mediated depletion for the therapy of EBL.

Indexed as

Antibodies, MonoclonalAntigens, CD20Enzootic Bovine LeukosisLymphoma, B-CellAnimalsAntibody-Dependent Cell CytotoxicityB-LymphocytesCattleCell Line, TumorHumansLeukemia Virus, BovineMiceAntibodies, MonoclonalAntigens, CD20CattleCD20CytotoxicityEnzootic bovine leukosisMonoclonal antibody

Identifiers

PMID42243279
PMCPMC13478501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.